This New Treatment Could Help Those With Chronic Yeast Infections
While it's not uncommon to develop a yeast infection at one point or another, some people experience upwards of four yeast infections over the course of a year, reports WebMD. Yeast infections of this frequency are categorized as recurrent yeast infections and are commonly treated with short-term use of antifungal creams, ointments, or oral medications (via the Mayo Clinic).
To relieve symptoms such as burning, pain while peeing, vaginal itching, and the presence of white discharge, some doctors will implement holistic treatment measures involving medications, probiotics, and changes in diet (via Healthline). Now, the US Food and Drug Administration (FDA) has authorized a new treatment method. Manufactured by Mycovia Pharmaceuticals, Inc., Vivjoa is an oral medication designed to treat those with recurrent yeast infections. FDA approval came after results of clinical trials revealed an overall success rate of 89.7% in the treatment of recurrent yeast infections in over 870 patients throughout 11 countries worldwide, reports Healthline.
However, the drug is intended for use within specific populations, so here's what you'll need to know before looking into a prescription.
Treatment is intended for limited populations
Split between two groups, study patients received either Vivjoa at the onset of infection and for 50 weeks following, or they received fluconazole for their initial infection, followed by a placebo treatment for 50 weeks (per Healthline).
In comparison to the nearly 90% success rate of the Vivjoa group, those in the fluconazole group had only a 57% success rate against recurrent yeast infections during the course of the study (via Healthline). Headaches and nausea were among the reported side effects.
As outlined by the drug manufacturers, Vivjoa is not intended for those of "reproductive potential," but rather for "persons who are biological females who are postmenopausal or have another reason for permanent infertility," as defined by Mycovia Pharmaceuticals, Inc. In addition, Vivjoa is not intended for use by those who are breastfeeding or pregnant, as the drug poses risks to fetal health.
Lead OB/GYN at MemorialCare Orange Coast Medical Center G. Thomas Ruiz tells Healthline that for those who are eligible, however, " ... this medication can be a gamechanger."